Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright‘s price objective points to a potential upside of 168.46% from the company’s previous close.
Actinium Pharmaceuticals Trading Down 9.1%
Shares of ATNM stock opened at $1.49 on Tuesday. Actinium Pharmaceuticals has a 12 month low of $0.74 and a 12 month high of $1.72. The stock has a market cap of $46.85 million, a P/E ratio of -1.07 and a beta of 0.27. The company has a 50 day simple moving average of $1.29 and a two-hundred day simple moving average of $1.13.
Institutional Trading of Actinium Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Compass Financial Management LLC bought a new position in shares of Actinium Pharmaceuticals in the second quarter worth about $588,000. BlackRock Inc. purchased a new position in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $388,000. Finally, Renaissance Technologies LLC grew its stake in shares of Actinium Pharmaceuticals by 20.7% during the 1st quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after acquiring an additional 80,816 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for patients with cancer, particularly blood cancers. Its approach combines cancer-targeting antibodies with radioactive isotopes intended to deliver radiation to specific cells. The company’s investigational programs include Iomab-B (apamistamab), an iodine-131-labeled antibody targeting CD45, developed as a conditioning treatment before a bone marrow transplant for certain patients with acute myeloid leukemia.
Read More
- Five stocks we like better than Actinium Pharmaceuticals
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
